

Gonzalo Crespo Conde

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4529298/publications.pdf>

Version: 2024-02-01

45
papers

1,066
citations

566801

15
h-index

414034

32
g-index

46
all docs

46
docs citations

46
times ranked

1829
citing authors

#	ARTICLE	IF	CITATIONS
1	Viral Hepatitis in Liver Transplantation. <i>Gastroenterology</i> , 2012, 142, 1373-1383.e1.	0.6	176
2	ARFI, FibroScan® [®] , ELF, and their combinations in the assessment of liver fibrosis: A prospective study. <i>Journal of Hepatology</i> , 2012, 57, 281-287.	1.8	150
3	Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. <i>Hepatology</i> , 2018, 67, 1683-1694.	3.6	114
4	The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. <i>Journal of Hepatology</i> , 2018, 69, 11-17.	1.8	80
5	Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation. <i>American Journal of Transplantation</i> , 2019, 19, 3176-3184.	2.6	60
6	Torque Teno Virus Is Associated With the State of Immune Suppression Early After Liver Transplantation. <i>Liver Transplantation</i> , 2019, 25, 302-310.	1.3	38
7	A propensity score-matched analysis of mortality in solid organ transplant patients with COVID-19 compared to non-solid organ transplant patients. <i>PLoS ONE</i> , 2021, 16, e0247251.	1.1	38
8	Usefulness of liver stiffness measurement during acute cellular rejection in liver transplantation. <i>Liver Transplantation</i> , 2016, 22, 298-304.	1.3	32
9	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 2513-2522.	2.6	32
10	Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List. <i>Transplantation</i> , 2020, 104, e188-e198.	0.5	30
11	Immune reconstitution syndrome after voriconazole treatment for cryptococcal meningitis in a liver transplant recipient. <i>Liver Transplantation</i> , 2008, 14, 1671-1674.	1.3	24
12	A notable proportion of liver transplant candidates with alcohol-related cirrhosis can be delisted because of clinical improvement. <i>Journal of Hepatology</i> , 2021, 75, 275-283.	1.8	23
13	Monitoring of miR-181a-5p and miR-155-5p Plasmatic Expression as Prognostic Biomarkers for Acute and Subclinical Rejection in de novo Adult Liver Transplant Recipients. <i>Frontiers in Immunology</i> , 2019, 10, 873.	2.2	21
14	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 107-114.	1.8	21
15	Prediction of Alcohol Relapse Among Liver Transplant Candidates With Less Than 6 Months of Abstinence Using the High-Risk Alcoholism Relapse Score. <i>Liver Transplantation</i> , 2019, 25, 1142-1154.	1.3	20
16	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013, 48, 762-769.	2.3	19
17	Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study. <i>Liver Transplantation</i> , 2021, 27, 1767-1778.	1.3	19
18	Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. <i>Liver International</i> , 2018, 38, 1940-1950.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Incidence, Predictors, and Impact on Survival of Long-term Cardiovascular Events After Liver Transplantation. <i>Transplantation</i> , 2020, 104, 317-325.	0.5	14
20	An objective definition for clinical suspicion of T cell-mediated rejection after liver transplantation. <i>Clinical Transplantation</i> , 2017, 31, e13005.	0.8	13
21	Lack of a 5.9 kDa Peptide C-Terminal Fragment of Fibrinogen α_2 Chain Precedes Fibrosis Progression in Patients with Liver Disease. <i>PLoS ONE</i> , 2014, 9, e109254.	1.1	12
22	Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2014, 61, 270-277.	1.8	11
23	Which preoperative assessment modalities best identify patients who are suitable for enhanced recovery after liver transplantation? A systematic review of the literature and expert panel recommendations. <i>Clinical Transplantation</i> , 2022, 36, e14644.	0.8	11
24	Rapidity of fibrosis progression in liver transplant recipients with recurrent hepatitis C is influenced by toll-like receptor 3 polymorphism. <i>Clinical Transplantation</i> , 2016, 30, 810-818.	0.8	8
25	MicroRNAs 155 α 5p, 122 α 5p, and 181 α 5p Identify Patients With Graft Dysfunction Due to T Cell-Mediated Rejection After Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1275-1286.	1.3	8
26	Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list. <i>Hepatology Communications</i> , 2022, 6, 1699-1710.	2.0	8
27	Patterns of kidney dysfunction in acute-on-chronic liver failure: Relationship with kidney and patients' outcome. <i>Hepatology Communications</i> , 2022, 6, 2121-2131.	2.0	8
28	Increased risk of portal vein thrombosis in patients with autoimmune hepatitis on the liver transplantation waiting list. <i>Clinical Transplantation</i> , 2017, 31, e13001.	0.8	7
29	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016, 29, 698-706.	0.8	5
30	Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus. <i>Liver Transplantation</i> , 2018, 24, 703-707.	1.3	5
31	IFNL4 polymorphism predicts response to hepatitis C treatment after liver transplantation. <i>Journal of Clinical Virology</i> , 2014, 61, 282-285.	1.6	4
32	Active Smoking Before Liver Transplantation in Patients with Alcohol Use Disorder: Risk Factors and Outcomes. <i>Journal of Clinical Medicine</i> , 2020, 9, 2710.	1.0	4
33	Modeling hepatitis C virus kinetics during liver transplantation reveals the role of the liver in virus clearance. <i>ELife</i> , 2021, 10, .	2.8	4
34	Results of a multidisciplinary strategy to improve the management of cardiovascular risk factors after liver transplantation. <i>Liver Transplantation</i> , 2022, 28, 1332-1344.	1.3	4
35	The Role of Arterial Stiffness in the Estimation of Cardiovascular Risk in Liver Transplant Recipients. <i>Transplantation Direct</i> , 2022, 8, e1272.	0.8	4
36	Manejo de la insuficiencia hepática aguda grave. Documento de posicionamiento de la Societat Catalana de Digestologia. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 51-64.	0.2	3

#	ARTICLE	IF	CITATIONS
37	Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review. <i>Infectious Diseases and Therapy</i> , 2021, 10, 1055-1064.	1.8	3
38	Neurotoxicity after liver transplantation: does donor age matter?. <i>Translational Gastroenterology and Hepatology</i> , 2021, 6, 0-0.	1.5	2
39	Moving Forward in the Stratification of Cardiac Risk in Liver Transplantation Candidates. <i>Liver Transplantation</i> , 2021, 27, 957-958.	1.3	2
40	Everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study. <i>Revista Espanola De Enfermedades Digestivas</i> , 2022, , .	0.1	2
41	Long-term outcomes after liver transplantation for ACLF – Don't forget quality of life!. <i>Liver International</i> , 2021, 41, 430-431.	1.9	1
42	The challenge of diagnosing Wilson's disease in patients with MAFLD. <i>Gastroenterology y Hepatología</i> , 2022, 45, 29-31.	0.2	1
43	Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation. <i>Journal of General Virology</i> , 2019, 100, 63-68.	1.3	1
44	Pre-transplant Cardiovascular Risk Assessment and Modification. Current Treatment Options in <i>Gastroenterology</i> , 0, , 1.	0.3	0
45	COVID-19, rejection, and cutaneous mucormycosis in a long-term liver transplant recipient – the vicious cycle of immunosuppression and opportunistic infections. <i>Journal of Liver Transplantation</i> , 2022, , 100113.	0.2	0